UPDATE - Barclays Downgraded Edwards Lifesciences (EW) to Equalweight; Cautious Around Rollout and Cohort 'A' Noise

September 23, 2011 2:07 PM EDT
Get Alerts EW Hot Sheet
Price: $111.96 +3.21%

Rating Summary:
    23 Buy, 14 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 14 | New: 72
Trade Now! 
Join SI Premium – FREE
UPDATE - Barclays downgraded Edwards Lifesciences (NYSE: EW) from Overweight to Equalweight, price target lowered from $95 to $85.

Barclays analyst says, "...Past the rollout, we think there could be volatility around the Cohort A panel in 1H12, given the July 2011 FDA panel's cautious stance on adverse events/stroke and an aggressive rollout of Cohort B. Net-net, while we continue to be positive on the long-term potential of the TAVR market, we think that the market could be slower to develop and upcoming risks could cause the stock to retrace."

To see more ratings changes on EW, Click Here


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Barclays